Sugi Predict

Sugi Predict / Compounds / SCHEMBL292553

SCHEMBL292553

SCHEMBL292553

CN(C)c1cccc2c(S(=O)(=O)CCOC(=O)OCCS(=O)(=O)c3cccc4c(N(C)C)cccc34)cccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ F2 P00734 3/20 0.51
▸ PRSS1 P07477 3/20 0.51
▸ PRSS2 P07478 3/20 0.51
▸ PRSS3 P35030 3/20 0.51
▸ PTGS2 P35354 1/20 0.47
▸ EDNRA P25101 6/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ KMT2A Q03164 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ HDAC4 P56524 1/20 0.45
▸ HDAC10 Q969S8 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ HDAC5 Q9UQL6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL292554 0.91 CA2 (0.51) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL5595985 0.90 CA2 (0.50) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL1282670 0.90 F2 (0.55) CA2CYP1A2CYP2C19HTTHIF1A
Hydrochloric Acid SCHEMBL8172567 0.88 CA2 (0.49) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL1861706 0.81 CA2 (0.59) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL732826 0.81 CA2 (0.52) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL3806560 0.80 CYP1A2 (0.63) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL13274117 0.79 CYP1A2 (0.71) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL1896953 0.79 CA2 (0.64) CA2CYP1A2CYP2C19HTTHIF1A
SCHEMBL7558145 0.79 CA2 (0.59) CA2CYP1A2CYP2C19HTTHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 — — EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 — — EP claimed
EP-4604951-A1 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF AMIRA THERAPEUTICS, S.L. (ES) 2025-08-27 — — EP disclosed
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 — — EP disclosed
US-12384800-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2025-08-12 — — US disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 — — US disclosed
WO-2025077996-A1 SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS PHARMA MAR, S.A. (ES) 2025-04-17 — — WO disclosed
US-12215100-B2 Anticancer compounds PHARMA MAR, S.A. (ES) 2025-02-04 — — US disclosed
EP-4419513-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2024-08-28 — — EP disclosed
US-12006311-B2 Compounds for use in preventing or treating cancer FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) 2024-06-11 — — US disclosed
US-20240166666-A1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2024-05-23 — — US disclosed
WO-2008153277-A1 POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2008-12-18 — — WO disclosed
EP-2001513-A1 THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF Korea Institute of Science and Technology (KR) 2008-12-17 — — EP disclosed
EP-1981544-A2 BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF KIST Korea Institute of Science and Technology (KR) 2008-10-22 — — EP disclosed
WO-2007144423-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2007-12-21 — — WO disclosed
WO-2007114549-A1 THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2007-10-11 — — WO disclosed
WO-2007083875-A2 BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2007-07-26 — — WO disclosed
US-20060173172-A1 Method for producing novel spinosyn derivatives JESCHKE PETER 2006-08-03 — — US disclosed
US-7034130-B2 Method for producing novel spinosyn derivatives BAYER CROPSCIENCE AG (DE) 2006-04-25 — — US disclosed
US-20040242858-A1 Method for producing novel spinosyn derivatives BAYER CROPSCIENCE AG (DE) 2004-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384800-B2 Antitumoral compounds TP53, TOP1, MCL1 CA2 2447/4885CYP1A2 2071/4885CYP2C19 1491/4885
US-20060173172-A1 Method for producing novel spinosyn derivatives COX15, SYVN1, CYP51A1 CA2 4851/4885CYP1A2 124/4885CYP2C19 401/4885
US-20040242858-A1 Method for producing novel spinosyn derivatives COX15, SYVN1, CYP51A1 CA2 4851/4885CYP1A2 124/4885CYP2C19 401/4885
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB CA2 2208/4885CYP1A2 1153/4885CYP2C19 1582/4885
US-20240166666-A1 ANTITUMORAL COMPOUNDS TP53, TOP1, MCL1 CA2 2447/4885CYP1A2 2071/4885CYP2C19 1491/4885
US-12006311-B2 Compounds for use in preventing or treating cancer UGT1A3, UGT1A1, UGT1A6 CA2 1624/4885CYP1A2 34/4885CYP2C19 168/4885
US-12215100-B2 Anticancer compounds TP53, MCL1, MYC CA2 3243/4885CYP1A2 1940/4885CYP2C19 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.